Russia reduces procurement of original anti-HIV drugs due to lack of funds

28 June 2022

Russia is reducing procurements of expensive Western original drugs for the treatment of HIV, switching to cheaper medicines, due to the lack of funds and the ever-growing number of patients with HIV in the country, reports The Pharma Letter’s local correspondent.

According to some Russian media reports, such budget for the current year of 30 billion roubles ($555 million) has already been exhausted: part of this amount was reserved in three-year contracts concluded in 2021 for the supply of raltegravir, Merck & Co’s (NYSE: MRK) Isentress, dolutegravir, GSK’s (LSE: GSK) Tivicay, and etravirine Johnson & Johnson’s (NYSE: JNJ) Intelence. This year, Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir) was purchased from Gilead Sciences (Nasdaq: GILD), which was included in the list of Vital and Essential Drugs in 2021.

However, despite this, the procurements of high-priced anti-HIV drugs in Russia is steadily declining.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK